

1/34




FIGURE 1A

2/34




FIGURE 1B




FIGURE 2A




FIGURE 2B

4/34

METDTLLLWVLLLWVPGSTGCDLPQTHSLGSRRTLMLLAQMRRISLFS
CLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAW
DETL LDKFYTELYQQ LNDLEACVIQGVGV TETPLMKEDSILAVRKYFQ
RITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE**SGRSDNI**
GGGSESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL
YSRLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLS
(SEQ ID NO:309)


FIGURE 3

5/34

METDTLLLWVLLLWVPGSTGCDLPQTHSLGSRRTLMLLAQMRRISLFS
CLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAW
DETLDDKFYTELYQQLNDEACVIQGVGVTTETPLMKEDSILAVRKYFQ
RITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKEISSGLLS
GRSDNI**GGGSE**SKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREPQVYTLP
PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDS
DGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS
(SEQ ID NO:311)

FIGURE 4

6/34

**FIGURE 5**

7/34




FIGURE 6

HEK293 reporter: Masked IFNa2b Fc fusions
111419HA




FIGURE 7

9/34

**EC50: Masked IFNa2b
N-terminal hlgG4 fusions
111419HA**




FIGURE 8A

**EC50: Masked IFNa2b
N-terminal hlgG4 fusions
111419HA**




FIGURE 8B




FIGURE 9

11/34

**EC50: Masked IFNa2b
N-terminal hlgG4 fusions
111419HA**




FIGURE 10A

**Daudi Cytotox EC50
IFNa2b hlgG4 fusions
111419HA**





FIGURE 10B

12/34

**FIGURE 11**

13/34





FIGURE 12

14/34

Daudi cells assay



HEK IFNa Reporter




FIGURE 13

15/34




FIGURE 14A





FIGURE 14B



HEK Reporter assay




FIGURE 15

18/34

C20-031: Growth of Daudi tumors






FIGURE 16



ATP: Daudi cells + IFNa2b
3 day treatment





FIGURE 17A



IFNa2bFc at N-Term 1 linker 1204DN




FIGURE 17B

PRO0291
...RSKESG6G6SGRSDNIGG6SESKYGFPCPC..
5AA 1204DL NiIG4 IFNa2b-hiG4
5AA 1204dL NiIG4 IFNa2b 5AA 1204dL NiIG4

	IFNa-con	ProC440+uPA	PEG-IFNa2b (Sylatron)	ProC440
Specific activity	1-2x10 ⁹ U/mg	3.5x10 ⁸ U/mg	0.7x10 ⁸ U/mg	1.3x10 ⁷ U/mg
Anticipated toxic dose	0.1 mpk*	0.288 mpk	1.43 mpk	7.68 mpk

FIGURE 18

22/34





FIGURE 19




FIGURE 20B

FIGURE 20A





FIGURE 21B

FIGURE 21A

25/34

2 mpk

○ Control = hlgG4


□ Test Article A = ProC286

△ Test Article B = ProC440

FIGURE 22

26/34

10 mpk




○ Control = hlgG4

□ Test Article A = ProC286

△ Test Article B = ProC440

FIGURE 22 cont.

27/34

**FIGURE 22 cont.**

28/34




FIGURE 23

29/34




FIGURE 23 cont.

30/34




FIGURE 23 cont.

31/34




FIGURE 24

32/34




FIGURE 24 cont.

33/34




FIGURE 24 cont.




FIGURE 25